Zusammenfassung
Die Hypertonie in der Schwangerschaft ist definiert als ein Blutdruck von systolisch ≥140 mmHg und diastolisch ≥90mmHg. Hypertone Blutdruckwerte finden sich bei 5–10% aller Schwangerschaften. Für den klinischen Gebrauch hat sich eine Klassifizierung der hypertensiven Schwangerschaftserkrankungen bewährt, die zwischen chronischer Hypertonie, Präeklampsie, Pfropfpräeklampsie und transienter Hypertonie unterscheidet. Die chronische bzw. vorbestehende Hypertonie ist definiert durch erhöhte Blutdruckwerte in der 1. Schwangerschaftshälfte und hat in der Mehrzahl der Fälle für den Ausgang der Schwangerschaft keine schwerwiegenden Konsequenzen.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
ACOG (1996) Hypertension in Pregnancy. ACOG Technical Bulletin 219
Atallah AN, Hofmeyr GJ, Dulay L (2000) Calcium supplementation during prgnancy for preventing hypertensive disorders and related problems (Cochrane Review) In: The Cochrane Library, Issue 1. Oxford Updated Software 2000
Atkinson MW, Belfort MA, Saade GR, Moise KJ (1994) The relation between magnesium sulfate therapy and fetal heart rate variability. Obstet Gynecol 83: 967–970
Barton JR, Sibai BM, Mabie WC, Shanklin DR (1990) Recurrent acute fatty liver of pregnancy. Am J Obstet Gynecol 163: 534–538
Baschat AA, Gambruch U, Harman CR (2001) The sequence of changes in Doppler and biophysical parameters as severe fetal growth restriction worsens. Ultrasound Obstet Gynecol 18: 581–577
Belizan JM, Villar J, Gonzalez L, Campodonica L, Bergel E (1991) Calcium supplementation to prevent hypertensive disorders of pregnancy. N Engl J Med 325: 1399–1405
Ben-Ami M, Giladi Y, Shalev E (1994) The combination of magnesium sulfate and nifedipine: a cause of neuromuscular blockade. Br J Obstet Gynaecol 101: 262–263
Bowen JR, Leslie Gl, Arnold JD, Jones MP, Gallery EDM (1988) Increased incidence of respiratory distress syndrome in infants following pregnancies complicated by hypertension. Aust NZ J Obstet Gynaecol 28: 109–112
Brown MA (1990) Non-pharmacological management of pregnancy-induced hypertension. J Hypertens 8: 295–301
Bücher HC, Guyatt GH, Cook RJ, Hatala R, Cook DJ, Lang JD, Hunt D (1996) Effect of calcium supplementation on pregnancy-induced hypertension and preeclampsia: a meta-analysis of randomized trials. J Am Med Assoc 275: 1113–1117
Chapell LC, Seed PT, Briley AL, Kelly FJ, Lee R, Hunt BJ, Parmar K, Bensley SJ, Shenaen AH, Steer PHJ, Poston L (1999) Effect of antioxidants on the recurrence of preeclampsia in women at increased sirsk: a random trial. Lancet 354: 810–816
Chesley LC, Annillo JE, Cosgrove RA (1976) The remote prognosis of preeclamptic women: sixth period report. Am J Obstet Gynecol 124: 446–459
Crowther CA (1985) Eclampsia at Harare Maternity Hospital. An epidemiologic study. South African Med J 68: 927–929
Davison JW (1991) Dialysis, transplantation and pregnancy. Am J Kidney Dis 17: 127–132
Dekker GA, de Vries JIP, Doelitzsch PM, Huijgens PC, von Blomberg BME, Jakobs C, van Geijn HP (1995) Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol 173: 1042–1048
Derks JB, Mulder EJH, Visser GHA (1995) The effects of maternal bethametasone administration on the fetus. Br J Obstet Gynaecol 102: 40–46
Douglas KA, Redman CWG (1994) Eclampsia in the United Kingdom. BMJ 309: 1395–1400
Eclampsia Trial Collaborative Group (1995) Which anticonvulsant for women with eclampsia ?. Evidence from the Collaborative Eclampsia Trial. Lancet 345: 1455–1463
Goffiuer F, Aboulkes D, Paris-Leado I, Bucourt M, Uzan M, Papiernik E, Bréast G (2001) Screening with uterine Doppler in low risk pregnant women followed by low dose aspirin in women with abnormal results: a multicenter, randomised controlled trial. Br j Obstet Gynecol 108: 510–518
Gray SE, Rodis JF, Lettieri L, Egan JFX, Vintzileos A (1994) Effect of intravenous magnesium sulfate on the biophysical profile in the healthy preterm fetus. Am J Obstet Gynecol 170: 1131–1135
Hall DR, Odendaal HJ, Steyn DW, Grevé D (2000) Expectant management of early onset, severe preeclampsia maternal outcome. Br J Obstet Gynecol 107: 1252–1257
Harper JMG, Murnaghan GA, Kennedy L, Hadden DR, Atkinson AB (1989) Phaeochromocytoma in pregnancy. Five cases and a review of the literature. Br J Obstet Gynaecol 96: 594–606
Hecher K, Bilardo CM, Stigter RH, Ville Y, Hackelöer BJ, Kok HJ, Senat MV, Visser GHA (2001) Monitoring fetuses with intrauterine growth restriction: a longitudinal study, ultrasound Obstet Gynecol 18: 564–570
Higgins JR, de Swiet M (2001) Blood-pressure measurement and classification in pregnancy. Lancet 357: 131–135
Howie PW, Prentice CRM, Forbes CD (1975) Failure of heparin therapy to affect the clinical course of severe pre-eclampsia. Br J Obstet Gynaecol 82: 711–717
Hüskes KP, Baumgartner A, Hardt U, Fink F (1991) Doppelseitige, mehrzeitige Spontanruptur der Leber bei HELLP-Syndrom. Chirurg 62: 221–222
Impey L (1993) Severe hypertension and fetal distress following sublingual administration of nifedipine to a patient with severe pregnancy induced hypertension at 33 weeks. Br J Obstet Gynaecol 100: 959–961
Inbar O, Blank M, Faden D, Tincani A, Lorber M, Shoenfeld Y (1993) Prevention of fetal loss in experimental antiphospholipid syndrome by low-molecular-weight heparin. Am J Obstet Gynecol 169: 423–426
Kennedy S, Hall P, Seymour A, Hague W (1994) Transient diabetes insipidus and acute fatty liver of pregnancy. Br J Obstet Gynaecol 101: 387–391
Knight M, Duley L, Henderson-Smart DL, King JF (2000) Antiplatelet agents and pre-eclampsia (Cochrane Review). In: The Cochrane Library, Issue 1, Oxford, updatet software, 2000
Kutteh WH (1997) Antiphospholipid antibodies and reproduction. J Reprod Immunol 35: 151–171
Levine RJ, Hanth JC, Curet LB et al. (1997) Trial of calcium to prevent preeclampsia. N Engl J Med 337: 69–76
Leviton A, Kuban KC, Pagano M et al. (1993) Antenatal corticosteroids appear to reduce the risk of postnatal germinal matrix hemorrhage in intubated low birth weight newborns. Pediatrics 91: 1083–1088
Liggins GC, Howie RN (1972) A controlled trial of antepartum glucocorticoid treatment for prevention of RDS in premature infants. Pediatrics 50: 515–525
Lockwood CJ, Rand JH (1994) The immunbiology and obstetrical consequences of antiphospholipid antibodies. Obstet Gynecol Surv 49: 432–441
Lubarsky SL, Barton JR, Friedman SA, Nasreddine S, Ramadan MK, Sibai BM (1994) Late postpartum eclampsia revisted. Obstet Gynecol 83: 502–505
Lucas MJ, Leveno KJ, Cunningham FG (1995) A comparison of magnesium sulfate with phenytoin for the prevention of eclampsia. N Engl J Med 333: 201–205
MacLean MA, Cameron AD, Cumming GP, Murphy K, Mills P, Hilan KJ (1994) Recurrence of acute fatty liver of pregnancy. Br J Obstet Gynaecol 101: 453–454
Magann EF, Bass D, Chauhan SO (1990) Accelerated recovery from severe preeclampsia: Uterine curettage versus Nifedipine. J Soc Gynecol Invest 1: 210–214
Magann EF, Martin JN, Isaacs JD, Perry KG, Martin RW, Mey-drech EF (1993) Immediate postpartum curretage: Accelerated recovery from severe preeclampsia. Obstet Gynecol 81: 502–506
Magann EF, Bass D, Chauhan SP, Sullivan DL, Nartin RW, Martin JN (1994a) Disease stabilisation in patients with the syndrome of hemolysis, elevated liver enzymes and low platelets (HELLP). Am J Obstet Gynecol 171: 1148–1153
Magann EF, Perry KG, Meydrech EF, Harris RL, Chauhan SP, Martin JN (1994b) Postpartum corticosteroids: accelerated recovery from the syndrome of hemolysis, elevated liver enzymes and low platelets (HELLP). Am J Obstet Gynecol 171: 1154–1158
Martin JN, Files JC, Blake PG, Norman PH, Martin RW, Hess WL, Morrison JC, Wiser WL (1990) Plasma exchange for preeclampsia I. Postpartum use for persistently severe preeclampsia-eclampsia with HELLP syndrome. Am J Obstet Gynecol 162: 126–137
Ment LR, Oh W, Ehrenkranz RA, Philip AGS, Duncan CC, Makuch RW (1995) Antenatal steroids, delivery mode, ans intraventicular hemorrhage in preterm infants. Am J Obstet Gynecol 172: 795–800
Mikhail MS, Anyaegbunam A, Garfinkel D, Palan PR, Basu J, Romney SL (1994) Preeclampsia and antioxidant nutritients: Decreased plasma levels of reduced ascorbic acid, a-Tocopherol, and ß-carotene in women with preeclampsia. Am J Obstet Gynecol 171: 150–157
Millar J, Campbell S, Albano J, Higgins B, Clark A (1996) Early prediction of pre-eclampsia by measurement of kallikrein and creatinine on a random urine probe. Br J Obstet Gynaecol 103: 421–426
Mushambi MC, Halligan AW, Williamson K (1996) Recent developments in the pathophysiology and management of pre-eclampsia. Br J Anaesth 76: 133–148
Nelson K, Grether JK (1995) Can Magnesium Sulfate reduce the risk of cerebral palsy in very low birthweight infants?. Pediatrics 95: 263–269
Ness RB, Roberts JM (1996) Heterogenous causes constituting the single syndrome of preeclampsia: A hypothesis and its implication. Am J Obstet Gynecol 175: 1365–1370
North R, Ferrier C, Long D, Townend K, Kinkaid-Smith P (1994) Prevention of preeclampsia with prophylactic heparin and anti-platelet agents in women with underlying renal disease. Hypertension in Pregnancy 13: 135–144
Odendaal HJ, Pattison RC, Bam R, Grove D, Kotze TJW (1990) Aggressive or expectant management for patients with severe preeclampsia between 28-34 weeks gestation: a randomized controlled trial. Obstet Gynecol 76: 1070–1076
Olson S, Sacher NJ, Tabor A, Weber T, Walker JJ, Gland C (2000) Randomised clinical trials of fisch oil supplementation in high-risk pregnancies. Br J Obsstet Gynecol 107: 382–395
Ounsted M (1988) The children of women who had hypertension during pregnancy. In: Rubin PC (ed) Hypertension in pregnancy. Elsevier, Amsterdam (Handbook of hypertension, vol 10, pp 341–362)
Pattison NS, Chamley LW, McKay EJ, Liggins GC, Butler WS (1993) Antiphospholipid antibodies in pregnancy: prevalence and clinical associations. Br J Obstet Gynaecol 100: 909–913
Papagorghiou At, Yu CKH, Binora R, Pandis G, Nicolaides KH (2001) Multicenter screening for preeclampsia and fetal growth restriction by transvaginal uterine artery Doppler at 23 weaks of gestation. Ultrasound Obstet Gynecol 18: 441–449
Pickard J, Jochen AL, Sadur CN, Hofeldt FD (1990) Cushing’s syndrome in pregnancy. Obstet Gynecol Surv 45: 87–93
Rath W, Loos W, Graeff H, Kuhn W (1992) Das HELLP-Syndrom. Gynäkologe 25: 430–440
Rath W, Loos W, Kuhn W (1994) Das HELLP-Syndrom. Zentralbl Gynäkol 116: 195–200
Redman CWG, Sacks GP, Sargent IL (1999) Preeclampsia: an axcessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 180: 499–506
Redman CWG (1995) Hypertension in pregnancy. In: De Swiet M (ed) Medical disorders in obstetric practice. Blackwell, Oxford, pp 182–225
Redman CWG, Ounsted MK (1982) Safety for the child of drug treatment for hypertension in pregnancy. Lancet 1: 1237
Report of the national high blood pressure education program working group an high blood pressure in pregnancy (2000) Am J Obstet Gynecol 183: 51–522
Rai R, Cohen H, Dave M, Regan L (1997) Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miss cariage associated with phospholipidantibodies (or antiphospholipidantibodies) BMO 324: 253–257
Rey E, Couturier A (1994) The prognosis of pregnancy in women with chronic hypertension. Am J Obstet Gynecol 171: 410–416
Reyes H, Sandoval L, Wainstein A, Ribalta J, Donoso S, Smik G (1994) Acute fatty liver of pregnancy: a clinical study of 12 episodes in 11 patients. Gut 35: 101–106
Riely CA (1987) Acute fatty liver of pregnancy. Semin Liver Dis 7: 47–54
Roberts JM, Hubel CA (1999) Is oxidative stress the link in the two-stage model of pre-eclampsia?. Lancet 354: 788–789
Robinson M (1958) Salt in pregnancy. Lancet 1: 178–181
Scardo JA, Hogg BB, Newman B (1995) Favorable hemodynamic effects of magnesium sulfate in preeclampsia. Am J Obstet Gynecol 173: 1249–1253
Schoeman MN, Batey RG (1991) Recurrent acute fatty liver of pregnancy associated with a fatty-acid oxidation defect in the offspring. Gastroenterology 100: 544–548
Sheehan HL (1940) The pathology of acute yellow atrophy and delayed chloroform poisoning. J Obstet Gynaecol Br Emp 47: 49–61
Sibai BM (1990) The HELLP-syndrome (hemolysis, elevated liver enzymes, and low platelets): Much ado about nothing?. Am J Obstet Gynecol 162: 311–316
Sibai BM (1996) Treatment of hypertension in pregnant women. N Engl J Med 335: 275–265
Sibai BM, El-Nazar A, Gonzalez-Ruiz A (1986a) Severe preeclampsia-eclampsia in in young primigravid women: subsequent pregnancy outcome and remote prognosis. Am J Obstet Gynecol 155: 1011–1016
Sibai BM, Abdella TN, Spinnato JA, Anderson GD (1986 b) Eclampsia V.The incidence of nonpreventable eclampsia. Am J Obstet Gynecol 154: 581–586
Sibai BM, Mercer B, Sarinoglu C (1991) Severe preeclampsia in the second trimester: Recurrence risk and long term prognosis. Am J Obstet Gynecol 165: 1408–1412
Sibai BM, Mercer BM, Schiff E, Friedman SA (1994) Aggressive versus expectant management of severe preeclampsia at 28-32 weeks gestation. Am J Obstet Gynecol 171: 818–822
Sibai BM, Ramadan MK, Chari RS, Friedman SA (1995) Pregnancies complicated by HELLP-Syndrome (hemolysis, elevated liver enzymes, and low platelets): subsequent pregnancy outcome and long-term prognosis. Am J Obstet Gynecol 172: 125–129
Steiner M (1989) Aktuelle Bilanz der mütterlichen Mortalität. In: Hillemanns HG, Schillinger H (Hrsg) Das Restrisiko gegenwärtiger Geburtshilfe. Springer, Berlin Heidelberg New York Tokyo, S 17–23
Steinhard J, Klockenbusch W (1999) Schwqangerschaftsinduzierte Hypertonie und Präeklampsie. Risikofaktoren und Vorhersagemöglichkeiten. Der Gynäkologe 10: 753–760
Sullivan CA, Magann EF, Perry KG, Roberst ME, Blake PG, Martin JN (1994) The recurrence risk of the syndome of hemolysis, elevated liver enzymes, and low platelets (HELLP) in subsequent gestations. Am J Obstet Gynecol 171: 940–943
Tuffneil DJ, Lilford RJ, Buchanan PC (1992) Randomised controlled trial of daycare for hypertension in pregnancy. Lancet 339: 224–227
Usta IM, Barton JR, Amon EA, Gonzalez A, Sibai BM (1994) Acute fatty liver of pregnancy: an experience in the diagnosis and management of fourteen cases. Am J Obstet Gynecol 171: 1342–1347
Uzan S, Beaufils M, Breart G, Bazic B, Capitant C, Paris J (1991) Prevention of fetal growth retardationwith low dose aspirin: findings of the EPREDAL trial. Lancet 337: 1427–1431
Vetter K, Kilavuz Ö (1999) Dopplersonografie und Präeklampsie. Der Gynäkologe 10: 761–767
Visser W, Wallenburg HCS (1995) Temporising management of severe preeclampsia with and without the HELLP syndrome. Br J Obstet Gynaecol 102: 111–117
Visser W, Wallenburg ACS (1995) Maternal and perinatal outcome of temporizing ménagement in 254 consecutive patients with severe preeclampsia remote from term. Eur J Obser Gynecol Reprod Biol 63: 147–153
Watson WJ, Seeds JW (1990) Acute fatty liver of pregnancy. Obstet Gynecol Surv 45: 585–593
Weinstein L (1982) Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy. Am J Obstet Gynecol 142: 159–167
Welsch H, Krone HA (1994) Mütterliche Mortalität und HELLP-Syndrom in Bayern 1982–1992. Zentralbl Gynäkol 116: 202–206
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Dürig, P. (2004). Hypertensive Schwangerschaftserkrankungen. In: Schneider, H., Husslein, P., Schneider, KT.M. (eds) Die Geburtshilfe. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18574-8_18
Download citation
DOI: https://doi.org/10.1007/978-3-642-18574-8_18
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-30522-4
Online ISBN: 978-3-642-18574-8
eBook Packages: Springer Book Archive